Medications

FDA approves Cobenfy for adults with schizophrenia

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Psychology & Psychiatry

Researchers explore social cognition in schizophrenia subtypes

A research team has explored the agreement or discrepancy between subjective social cognitive difficulties and actual cognitive impairment. Their study aimed to identify clinical subtypes in patients with schizophrenia, and ...

Psychology & Psychiatry

FDA approves new kind of drug for schizophrenia

The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and. Drug Administration.

page 2 from 40